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The recognition of a case of childhood tuberculosis (TB) is 
a sentinel public event. It reflects a poor adult TB control 
programme, a marker of other diseases, e.g. HIV, provides a 
reservoir for future cases of TB, an opportunity to undertake 
contact tracing and a need for action in child health. Childhood 
TB accounts for 11% (884 000 cases) of the global burden of 
TB, with Africa accounting for 27% of the global cases despite 
having just 11% of the world’s population. South Africa has 
the seventh highest global burden of TB with an incidence of 
600/100 000.  
Of the 2.8 million cases of childhood HIV disease, 2.2 million 
(> 80%) live in sub-Saharan Africa (SSA). There are 665 000 new 
childhood infections and 450 000 deaths (3%) globally from 
HIV each year despite effective strategies for the prevention 
of mother-to-child transmission. In SSA, only 6% of children 
deserving antiretroviral drugs receive therapy; consequently 
HIV disease accounts for 6% of all deaths in children younger 
than 5 years of age. In South Africa, of the 240 000 HIV-infected 
children only 10 - 15% receive treatment.
The incidence of TB in HIV-uninfected persons is 
656/100 000 person years while in HIV-infected persons it 
is 4 381/100 000 person years. In South Africa, the incidence 
of both TB and HIV is increasing exponentially, with each 
epidemic fuelling the other (4.3- and 3.5-fold increase for 
TB and HIV respectively). The risk of acquiring TB is 10% 
per annum in HIV-infected children while for an HIV-
uninfected child it is 10% per lifetime. The impact of HIV 
on TB prevalence is clearly seen with the increase in the 
prevalence of congenital TB, paucibacillary or smear-negative 
TB, extrapulmonary TB, reactivation and reinfection TB and 
immune reconstitution inflammatory syndrome (IRIS). 
Diagnostic criteria for TB and HIV 
disease in childhood 
The diagnosis of childhood TB has always been difficult 
to confirm; this is compounded in HIV-infected children. 
Several practical advances to assist in the diagnosis have 
recently been made. Contact with an infectious source TB 
case has been explored in terms of duration of exposure, 
degree of infectivity, drug susceptibility, and nutritional and 
immunological status of the index case. The recognition that 
10 - 15% of acute pneumonia cases are due to TB and increased 
incidence of clubbing in HIV and TB co-infected children 
has allowed for a heightened suspicion of the diagnosis of 
TB. However, overlapping clinical and radiological features 
and poor sensitivities for the tuberculin skin test (TST) make 
confirmation of TB difficult. The TST has a sensitivity of 58% 
in HIV-uninfected and just 26% in HIV-infected children. 
Its sensitivity is affected by BCG, age, degree of immune 
suppression, poor nutrition and environmental mycobacterium. 
The T-lymphocyte-based immune releasing assays measuring 
specific antigens, e.g. early secretory antigen target 6 (ESAT 
6), culture filtered protein 10 (CFP10) or Resat have shown 
promise in HIV-infected individuals. Two types of interferon-
gamma releasing assays (IGRA) are commercially available, the 
Quantiferon TB Gold and the Elispot T-spot based assays. The 
former test appears to be superior to TST in HIV-uninfected 
children, but is less useful in HIV-infected children with low 
sensitivity (17%) and specificity (38%). The Elispot T test 
has a sensitivity of 52% in HIV-infected children. Further 
comparative studies are needed to confirm these findings. 
In comparison with the TST, the IGRA appears to be slightly 
better in detecting TB infection (51% v. 73 - 85%), although the 
combination of the IGRA and TST was useful in confirming a 
diagnosis of TB infection in 91.4% of children. A negative IGRA 
and TST would help exclude the diagnosis of TB and could 
reduce over-diagnosis by almost one-third. 
  As regards microbiological detection of Mycobacterium 
tuberculosis, the use of the radiometric mycobacterium liquid 
culture system (MGIT) has increased the yield of TB in a 
suitable specimen to 97% within 9.5 to 14 days; its value in 
HIV-infected children has not yet been evaluated. Histological 
findings on biopsy for TB in HIV-infected children include ill-
defined caseous granulomas with epitheloid histiocytes.
Management of TB and HIV disease
Several major issues related to the combined use of anti-
TB and antiretroviral therapy have been studied recently. 
Concerns relating to pill burden, adverse drug reactions, drug 
interactions and IRIS have been identified. The commencement 
of highly active antiretroviral therapy (HAART) in a child 
being treated for TB is best undertaken after the completion 
of anti-TB therapy, provided the child’s condition allows this. 
This limits drug interactions and adverse effects between 
HAART and anti-TB drugs. In children with WHO stage 4 
disease or a CD4 count within 5% of severe immunodeficiency 
(200 - 349 cells/µl) HAART should be commenced as soon as 
possible after the TB treatment is tolerated, i.e. during in the 
initiation phase of anti-TB treatment. Children with WHO 
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stage 3 disease or with a CD4 count above 349 cells/µl or 
> 5% above severe immunodeficiency, HAART should be 
commenced during the maintenance phase of anti- TB therapy. 
In a child receiving HAART who develops TB, HIV treatment 
failure should first be ruled out. After this one should decipher 
whether reinfection/reactivation, primary TB or IRIS has 
occurred.  In those on first-line therapy, i.e. stavudine (4dT), 
lamivudine (3TC), and efavirenz/nevirapine (EFV/NVP), a 
possible change to a triple nucleoside reverse transcriptase 
inhibitor regimen could be considered, although the efficacy 
of this regimen is just 79% and abacavir has been associated 
with acute pneumonitis. A second option includes the changing 
of NVP to EFV, or increasing the dose of NVP by 25 - 33% to 
accommodate the faster metabolism of NVP in the presence 
of anti-TB therapy. This option carries an increased risk of 
hepatotoxicity, making monitoring for adverse effects essential. 
In patients on second-line agents, i.e. zidovudine (AZT), ddI 
and Kaletra, a 33% increase in the dose of ritonavir is required 
to combat drug interaction between rifampicin and protease 
inhibitors (PI). The PI dose should be slowly increased over a 
week. 
Anti-TB drugs and HAART have similar toxicity effects. 
These include nausea (ddI, AZT, ritonavir, PZA), peripheral 
neuropathy (d4T, ddI, INH), rash (NVP, abacavir, INH) and 
hepatitis (rifampicin, NVP, PI).
Drug resistance to both HAART and anti-TB therapy is a 
third major issue. The criteria for resistance testing of children 
on HAART include clinical failure on a second-line regimen, 
virological failure (increased HIV viral load on two samples 
taken 1 month apart) and children who are adherent (pill count 
or diary entries). Innate resistance to antiretroviral agents has 
been seen. Acquired resistance commonly K184V mutations 
to 3TC and K103N to NVP is seen after structured drug 
interruption, use of inefficient regimens or poor adherence. 
Single- or multiple-drug mutations with class effects have been 
recorded.
Resistance to anti-TB drugs is common and increasing. 
Initial (ab initio) drug resistance is seen in 1 - 4%, secondary 
(post drug utilisation) resistance in 10 - 15%, and multidrug 
(rifampicin and INH) resistance in 2 - 6% of cases. Extensively 
drug-resistant TB (XDR TB) (resistance to a flouroquinolone 
and any of the other second-line anti-TB agents) is 
predominantly seen in HIV-infected adults. Transmission of 
these resistance strains is increasing, causing severe disease in a 
proportion of cases.
It is recommended that HIV-infected children receive 
standard regimens as suggested by the National Tuberculosis 
Programme. However, some modifications should be 
considered. Firstly, an additional 5 mg/kg dose of INH should 
be added to the recommended fixed-drug combination during 
the intensive stage of therapy because of fast acetylating of 
INH in childhood. Secondly, the high end of the dosing range 
for all drugs should be used in HIV-infected children. Thirdly, 
a reactivation or reinfection TB regimen must be considered 
for children on their second or third courses of anti-TB therapy. 
Fourthly, at the end of 6 months’ treatment the children must 
be carefully evaluated as prolonged use of anti-TB therapy may 
be needed. It should be remembered that radiological changes 
may persist at this time, even if the patient is cured.
The role of chemoprophylaxis in children in many high-
burden countries has been very controversial. The current 
recommendation for use of chemoprophylaxis in HIV-infected 
children includes all children with a positive TST or those 
in contact with an infectious case of TB after active disease 
was excluded. A recent placebo-controlled randomised trial 
from Cape Town showed HIV-infected children on INH 
prophylaxis had lower all-cause mortality than children on 
placebo although the deaths in the placebo group did not have 
TB. Further studies are required. The current regimens for TB 
prophylaxis include INH 5 mg/kg for 6 months or INH and 
rifampicin 10 mg/kg each for 3 months
The directly observed therapeutic strategy (DOTS) has been 
advocated by the WHO as a major advance in the control of the 
epidemic. In parts of South East Asia, this strategy has revealed 
significant benefit in the control of the TB epidemic while in 
most parts of Africa, a poor yield in the control of the epidemic 
has been realised. This difference is attributed to the resources 
utilised in the programmes in the two regions. DOTS for HIV 
and TB could be combined as a joint public private health 
initiative.
The use of BCG in HIV-infected children has recently been 
shown to be associated with an increased incidence of between 
400 and 800 per 100 000 cases of disseminated BCGosis. The 
safety committee of WHO have therefore recommended that 
BCG vaccine should not be used in children who are known to 
be HIV infected. BCG should be continued to be administered 
at birth where the HIV status cannot be determined during 
early infancy.  Careful monitoring for disseminated disease 
should be instituted where BCG vaccine is administered. 
Congenital tuberculosis
The incidence of congenital TB has increased 5-fold since 
the onset of the HIV epidemic. This is parallel to an increase 
in the incidence of TB in HIV-infected women during 
pregnancy (774/100 000) as compared with the TB incidence 
of 74/100 000 in HIV-uninfected pregnant women. Perinatal 
transmission of TB occurs at a rate of 10 - 15% and increases 
by 5 - 6-fold if appropriate care is not provided for the mother. 
Certain anti-TB therapy such as quinolones, ethionamide, 
cycloserine, terizidone, PAS and potentially aminoglycosides 
are toxic in pregnancy and should not be used. EFV has been 
shown to be teratogenic while NVP has been associated with 
hepatotoxicity in pregnancy. Congenital TB could be acquired 
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in utero, during delivery or post partum. A case of congenital 
TB could be identified either from exposure to the TB-infected 
mother or as an index case in a sick newborn. Diagnosis of 
congenital TB is made according to the criteria of Cantwell. 
Features of early presentation include prematurity, growth 
retardation, pneumonia and hepatic disease in the first week. 
The diagnosis is confirmed when genital tract TB disease in the 
mother is diagnosed. Late presentation at 3 - 4 weeks includes 
hepatosplenomegaly, lymphadenopathy, chronic pneumonia, 
disseminated infection, seizures, skin TB and jaundice. 
Management of HIV and TB in the neonatal period is complex 
and these cases should be referred.
Conclusion
HIV infection has altered the incidence and presentation of 
childhood TB. The incidence of congenital TB, extrapulmonary 
TB and reactivation/reinfection disease is increasing.  The 
diagnosis of TB in HIV-infected children is difficult. Treatment 
of HIV and TB co-infected children is challenging with 
adverse drug reactions and drug interactions being common. 
Chemoprophylaxis and immunisation require further 
evaluation.
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